• Browse the complete index of our coverage.

• Download the PDF version of our complete conference coverage (600K).

After the release of the guidelines is there a different understanding of when's the best time to start treatment? Judy Aberg, M.D., reports from ICAAC.

In a large comparison study of 1,119 antiretroviral-naive patients who started HIV therapy, treatment regimens containing efavirenz, nevirapine or Kaletra were found to be the most potent options. Gerald Pierone, Jr., M.D., reports."

"Both resistance testing and therapeutic drug monitoring are crucial tools to manage both treatment-naive and treatment-experienced patients. Mark Holodniy, M.D., explains why."

A Spanish study confirms ACTG 5095 and finds that the three-nucleoside regimen in Trizivir was not quite as potent as the efavirenz- or nevirapine-containing regimens for initial therapy. Andrew Pavia, M.D., reports.

The Body's ICAAC 2003 coverage spans a wide array of individual presentations and symposia, as well as research summaries of some of the hottest topics in HIV research. For more information on ICAAC, please visit the conference's Web site. You may also view the conference's preliminary program online or download it in PDF form (3.3MB). Funding for coverage of this conference is provided, in part, by unrestricted educational grants from Boehringer Ingelheim, Gilead Sciences, Inc., GlaxoSmithKline and Ortho Biotech Products, L.P. All coverage is © 2003 Body Health Resources Corporation.